IN
INVA.US Innoviva Inc
- Market cap
- USD 1.35B
- P/E
- 8.1x
- P/B
- 1.19x
- ROE
- 3.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INVA.US undervalued?
Graham numberINVA.US trades 34.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innoviva Inc fundamental analysis
No fundamental analysis for Innoviva Inc yet.
Innoviva Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic o…
Full company profileInnoviva Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innoviva Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 134M | 217M | 261M | 261M | 337M | 392M | 331M | 310M | 359M | 425M | 432M |
| Gross Profit | 132M | 217M | 261M | 261M | 337K | 392M | 318M | 268M | 322M | 308M | 334M |
| Operating Income | 109M | 184M | 238M | 246M | 321M | 375M | 207M | 114M | 167M | 164M | 175M |
| EBITDA | 123M | 192M | 237M | 232M | 317M | 361M | 322M | 249M | 99.5M | 384M | 496M |
| Net Income | 59.5M | 134M | 395M | 157M | 224M | 266M | 214M | 180M | 23.4M | 271M | 39.0M |
| EPS | 0.48 | 1.12 | 3.48 | 1.39 | 1.98 | 2.82 | 2.25 | 2.07 | 0.32 | 3.20 | 0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 379M | 367M | 548M | 725M | 1,000M | 926M | 1.23B | 1.24B | 1.30B | 1.64B | 1.54B |
| Total Liabilities | 732M | 610M | 389M | 383M | 392M | 400M | 666M | 569M | 610M | 462M | 400M |
| Shareholders' Equity | -353M | -243M | 154M | 313M | 608M | 415M | 566M | 675M | 691M | 1.17B | 1.14B |
| Cash & Short-term Investments | 150M | 129M | 115M | 351M | 246M | 202M | 291M | 194M | 412M | 551M | 590M |
| Total Debt | 716M | 599M | 383M | 377M | 411M | 395M | 544M | 449M | 451M | 269M | 270M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 61.0M | 142M | 224M | 257M | 313M | 364M | 202M | 141M | 189M | 197M | 172M |
| Capital Expenditure | 278K | 12.0K | 12.0K | 12.0K | 13.0K | 1.30M | 67.0K | 411K | 270K | 10.5M | 1.26M |
| Free Cash Flow | 60.7M | 142M | 224M | 257M | 313M | 363M | 202M | 141M | 188M | 186M | 171M |
| Ratios | |||||||||||
| ROE | - | - | 257.2% | 50.2% | 36.9% | 64.1% | 37.8% | 26.6% | 3.4% | 23.1% | 3.4% |
| ROA | 15.7% | 36.5% | 72.1% | 21.7% | 22.4% | 28.7% | 17.4% | 14.5% | 1.8% | 16.6% | 2.5% |
| Net Profit Margin | 44.6% | 61.8% | 151.4% | 60.3% | 66.6% | 67.8% | 64.6% | 57.9% | 6.5% | 63.8% | 9.0% |
| Debt to Equity | - | - | 2.49x | 1.20x | 0.68x | 0.95x | 0.96x | 0.67x | 0.65x | 0.23x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Innoviva Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 8, 2015
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 96.3M | 1.11 | 53.6% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 11.0K | 0.00 | 0.0% |
| 2018 | USD 80.0K | 0.00 | 0.0% |
| 2017 | USD 281K | 0.00 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1241:1000 on Jun 3, 2014.
Who owns Innoviva Inc
- Insiders 2.40%
- Institutions 97.60%
- Public & others 0.00%
- Shares outstanding 71.1M
- Free float 66.9M
Top funds holding INVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.34M | 6.11% | -0.21% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.23M | 3.14% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.90M | 2.68% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.55M | 2.17% | -3.97% | Sep 2026 |
| DFA U.S. Small Cap Value I | 1.44M | 2.02% | +42.67% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 1.01M | 1.41% | -1.85% | Sep 2026 |
| Invesco Pharmaceuticals ETF | 833K | 1.17% | +0.45% | Oct 2026 |
| Fidelity Small Cap Index | 827K | 1.16% | +0.20% | Aug 2026 |
| iShares Russell 2000 Value ETF | 710K | 1.00% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 656K | 0.92% | -0.05% | Oct 2026 |
| DFA U.S. Targeted Value I | 551K | 0.78% | 0.00% | Sep 2026 |
| Dimensional US Targeted Value ETF | 507K | 0.71% | 0.00% | Oct 2026 |
| VictoryShares US Sm Md Cp Val Momt ETF | 460K | 0.65% | +0.29% | Oct 2026 |
| Vanguard Russell 2000 ETF | 439K | 0.62% | +1.12% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 438K | 0.62% | +2.88% | Oct 2026 |
| Dimensional US Small Cap Value ETF | 431K | 0.61% | +0.04% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 403K | 0.57% | 0.00% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 386K | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 383K | 0.54% | +0.23% | Oct 2026 |
| Avantis US Small Cap Value ETF | 374K | 0.53% | 0.00% | Oct 2026 |
Top institutions holding INVA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 11.6M | 16.26% | +2.19% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 4.51M | 6.35% | +0.42% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 4.22M | 5.94% | -0.11% | Jun 2026 |
| Renaissance Technologies Corp | 3.65M | 5.14% | -9.57% | Sep 2026 |
| State Street Corp | 3.27M | 4.60% | +6.78% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.16M | 4.44% | +0.52% | Jun 2026 |
| Millennium Management LLC | 2.54M | 3.57% | +11.48% | Jun 2026 |
| Geode Capital Management, LLC | 2.07M | 2.92% | +7.51% | Jun 2026 |
| Systematic Financial Management LP | 2.02M | 2.85% | -0.03% | Jun 2026 |
| Boston Partners Global Investors, Inc | 1.93M | 2.71% | +12.16% | Jun 2026 |
| Sarissa Capital Management LP | 1.89M | 2.66% | -11.28% | Jun 2026 |
| Bank of America Corp | 1.67M | 2.35% | +2.94% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.62M | 2.28% | +1.68% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.45M | 2.05% | -3.33% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.22M | 1.72% | -6.86% | Jun 2026 |
| Royce & Associates, LP | 1.17M | 1.65% | +10.48% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.15M | 1.62% | -1.07% | Jun 2026 |
| Two Sigma Investments LLC | 1.03M | 1.45% | -30.42% | Jun 2026 |
| Qube Research & Technologies | 974K | 1.37% | +23.92% | Jun 2026 |
| Deutsche Bank AG | 918K | 1.29% | +1.09% | Jun 2026 |
Innoviva Inc company profile
- Company name
- Innoviva Inc
- Ticker
- INVA.US
- Exchange
- USA Stocks
- Listed since
- Oct 5, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 159
- Fiscal year end
- December
- Address
- 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010
- Phone
- 650 238 9600
- Website
- inva.com
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva Inc management
5- Mr. Pavel Raifeld C.F.A.CEO & Director · born 1984
- Mr. Stephen Basso M.B.A.Chief Financial Officer · born 1966
- Ms. Marianne Zhen CPAChief Accounting Officer & Secretary · born 1969
- Ms. Patricia M. DrakeChief Commercial Officer-Innoviva Specialty Therapeutics, Inc. · born 1967
- Dr. David Altarac M.D., MPAChief Medical Officer of IST · born 1962